Rapamycin enhances eIF4E phosphorylation by activating MAP kinase‐interacting kinase 2a (Mnk2a)
- 4 July 2013
- journal article
- Published by Wiley in FEBS Letters
- Vol. 587 (16), 2623-2628
- https://doi.org/10.1016/j.febslet.2013.06.045
Abstract
Eukaryotic initiation factor eIF4E and its phosphorylation play key roles in cell transformation and tumorigenesis. eIF4E is phosphorylated by the Mnks (MAP (mitogen-activated protein) kinase-interacting kinases). Rapamycin increases eIF4E phosphorylation in cancer cells, potentially limiting their anti-cancer effects. Here we show that the rapamycin-induced increase in eIF4E phosphorylation reflects increased activity of Mnk2 but not Mnk1. This activation requires a novel phosphorylation site in Mnk2a, Ser437. Our findings have potentially important implications for the use of rapamycin and its analogues in cancer therapy, suggesting that inhibitors of mTOR and Mnk (or Mnk2) may be more efficacious than rapalogs aloneKeywords
Funding Information
- Gerald Kerkut Trust
This publication has 33 references indexed in Scilit:
- Targeting Mnks for Cancer TherapyOncotarget, 2012
- mTOR inhibitors in renal cell carcinomaTherapy, 2011
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2PLoS Biology, 2009
- The TSC1–TSC2 complex: a molecular switchboard controlling cell growthBiochemical Journal, 2008
- Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer TherapyCancer Research, 2008
- Signalling to translation: how signal transduction pathways control the protein synthetic machineryBiochemical Journal, 2007
- When translation meets transformation: the mTOR storyOncogene, 2006
- The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesisNature Medicine, 2004
- Survival signalling by Akt and eIF4E in oncogenesis and cancer therapyNature, 2004
- Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' capNature, 1990